You are here

RNAi

Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug

Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug

Fierce Biotech

Dicerna Pharmaceuticals

Flag link:

Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn

Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn

Fierce Pharma

Flag link:

RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round

RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round

CP Wire

cholangiocarcinoma

hepatocellular carcinoma

Flag link:

Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases

Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases

Xconomy

Flag link:

After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise

After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise

Endpoints

John Maraganore

Flag link:

Data in Hand, Alnylam To Seek OK For Second RNAi Drug

Data in Hand, Alnylam To Seek OK For Second RNAi Drug

Xconomy

acute hepatic porphyria

Flag link:

Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018

Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018

Motley Fool

Arrowhead Pharmaceuticals

Flag link:

Alnylam CEO talks politics, gene therapy and not becoming Pfizer

Alnylam CEO talks politics, gene therapy and not becoming Pfizer

BioPharma Dive

John Maraganore

Flag link:

Here's Why Arrowhead Pharmaceuticals Jumped 14.1% in November

Here's Why Arrowhead Pharmaceuticals Jumped 14.1% in November

Motley Fool

Arrowhead Pharmaceuticals

Flag link:

Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst

Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst

Fierce Pharma

hATTR amyloidosis

Flag link:

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Pharmaceutical Business Review

Flag link:

Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug

Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug

Fierce Biotech

Flag link:

RNAi company Dicerna raises $100M follow-on

RNAi company Dicerna raises $100M follow-on

BioCentury

Dicerna Pharmaceuticals

Flag link:

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

Xconomy

Flag link:

Sirnaomics cleared to start first trial of RNAi lead in cancer

Sirnaomics cleared to start first trial of RNAi lead in cancer

Fierce Biotech

Flag link:

3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug

3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug

Motley Fool

Flag link:

After Alnylam’s solo maiden launch, here comes the tricky bit

After Alnylam’s solo maiden launch, here comes the tricky bit

EP Vantage

Flag link:

In first, FDA approves RNA interference drug from Alnylam

In first, FDA approves RNA interference drug from Alnylam

Biopharma Dive

hATTR amyloidosis

Flag link:

With patisiran launch in its sights, Alnylam plots a major hiring spree

With patisiran launch in its sights, Alnylam plots a major hiring spree

Fierce Pharma

Flag link:

Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal

Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal

Endpoints

Axovant Sciences

Flag link:

Pages